04 June 2018
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 71,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List.
These Shares are being reserved under a block listing and will be issued pursuant to the following scheme:
Scheme Shares
Unapproved Share Scheme 36,000
Long Term Incentive Plan (LTIP) 35,000
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 5 June 2018.
For further information
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.